# Cumberland Pharmaceuticals Inc. (CPIX) · Edgar & Edgarette company card

> Cumberland Pharmaceuticals (CPIX) grew revenue 17.6% in FY2025 to $45 million, operating margin -6.3% against a -3.8% median for pharmaceutical preparations, equity 32.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1087294 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CPIX) · [JSON](https://www.pops4.com/boards/company/CPIX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $45M |
| Revenue growth, 1 year | 17.6% |
| Revenue growth per year | 5.5% |
| Operating margin | -6.3% (prior year -17.0%) |
| Net margin | -6.4% |
| Operating cash flow | $5M |
| Capital spending | $97,903 |
| Free cash flow | $5M |
| Cash | $11M |
| Long-term debt | — |
| Total assets | $77M |
| Total equity | $25M |
| Equity ÷ assets | 32.4% |
| Return on equity | -11.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.86 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.64 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -6.3% in FY2025; revenue is hard to predict: its 80% range is ±37%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $44.5M (FY2025). Experience: revenue up 17.6% on the year, up 5.5% a year over 4 years; operating margin -6.3%, up from -17.0%. Soundness: equity 32.4% of assets, return on equity -11.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $32.3M and $70.8M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $30.6M to $74.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6.3% against a -3.8% median; growth 17.6% against 13.7%.

Range logged 2026-09-29, receipt d2b383fe52686c29, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-07-01 ([filing](https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm))

## Recent filings

- 8-K · filed 2026-10-26 · 7.01 Regulation FD Disclosure; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000072/0001087294-26-000072-index.htm)
- 8-K · filed 2026-10-23 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000070/0001087294-26-000070-index.htm)
- 8-K · filed 2026-08-28 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/0001087294-26-000064-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000062/0001087294-26-000062-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/0001087294-26-000058-index.htm)
- 8-K · filed 2026-07-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000055/0001087294-26-000055-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001087294.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1087294

## Cite

POPS4, Edgar & Edgarette: Cumberland Pharmaceuticals Inc. (CPIX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CPIX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.